Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare ovarian cancer: immunotherapy combo tested in phase II trial

NCT ID NCT06023862

Recruiting now Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing whether the immunotherapy drug dostarlimab, alone or combined with bevacizumab, can control recurrent gynecological clear cell carcinoma better than standard chemotherapy. About 198 women with this rare cancer type will be randomly assigned to one of three groups. The study aims to see if these newer treatments can delay cancer progression and improve response rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Dostarlimab (immunotherapy) and bevacizumab (anti-angiogenic drug)
What this could lead to
If successful, this could offer a new, less toxic treatment option for women with recurrent gynecological clear cell carcinoma, potentially improving how long they live without the cancer growing.
What could go wrong
This is a phase II trial, so it's still early. The drugs may not work better than standard chemotherapy, and immunotherapy can cause immune-related side effects like inflammation in organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical clear cell adenocarcinoma clear cell adenocarcinoma endometrial clear cell adenocarcinoma endometrium neoplasm ovarian cancer ovarian clear cell cancer ovarian neoplasm Uterine Cervical Neoplasms uterine cervix neoplasm vaginal adenocarcinoma vaginal cancer vaginal neoplasm vulva cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLEAR CELL CARCINOMA ENDOMETRIAL NEOPLASMS OVARIAN NEOPLASMS UTERINE CERVICAL NEOPLASMS VAGINA NEOPLASM VULVAR CANCER

Contacts and locations

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, South Korea

  • Bundang Seoul National University Hospital

    RECRUITING

    Seongnam-si, South Korea

  • Calvary Mater Newcastle

    ACTIVE_NOT_RECRUITING

    Waratah, Edith Saint, Australia

  • Chang Gung Memorial Hospital

    ACTIVE_NOT_RECRUITING

    Taipei, Songshan District, Taiwan

  • Fukushima Medical University Hospital

    RECRUITING

    Fukushima, Fukushima, 960-1295, Japan

  • Guy's and St Thomas' NHS Foundation Trust

    ACTIVE_NOT_RECRUITING

    London, Monkton, United Kingdom

  • Korea University Guro Hospital

    RECRUITING

    Seoul, South Korea

  • Kurume University Hospital

    RECRUITING

    Kurume, Fukuoka, 830-0011, Japan

  • Mie University Hospital

    RECRUITING

    Tsu, Mie-ken, 514-8507, Japan

  • Monash Medical Centre

    ACTIVE_NOT_RECRUITING

    Clayton, Clayton Rd., Australia

  • National Cancer Center

    RECRUITING

    Goyang-si, South Korea

  • National Taiwan University Hospital

    ACTIVE_NOT_RECRUITING

    Taipei, Zhongzheng, Taiwan

  • National University Hospital

    ACTIVE_NOT_RECRUITING

    Singapore, Kent Ridge Rd, Singapore

  • National University Hospital

    NOT_YET_RECRUITING

    Singapore, Singapore

  • Niigata Cancer Center Hospital

    RECRUITING

    Niigata, Niigata, 951-8566, Japan

  • Peter MacCallum Cancer Centre

    ACTIVE_NOT_RECRUITING

    Melbourne, Grattan Saint, Australia

  • Saitama Medical University International Medical Center

    RECRUITING

    Hidaka, Saitama, 1397-1, Japan

  • Samsung Medical Center

    RECRUITING

    Seoul, South Korea

  • Seoul National University

    RECRUITING

    Seoul, South Korea

  • Severance Hospital, Yonsei Health System

    RECRUITING

    Seoul, Seoul, 03722, South Korea

  • Taipei Veterans General Hospital

    ACTIVE_NOT_RECRUITING

    Taipei, Beitou District, Taiwan

  • The Cancer Institute Hospital Of JFCR

    RECRUITING

    Tokyo, Tokyo, 135-8550, Japan

  • The Jikei University Hospital

    RECRUITING

    Tokyo, Tokyo, 105-0003, Japan

  • Tohoku University Hospital

    RECRUITING

    Sendai, Miyagi, 980-8574, Japan

  • Tokushima University Hospital

    RECRUITING

    Tokushima, Tokushima, 770-8501, Japan

  • University of Hong Kong

    ACTIVE_NOT_RECRUITING

    Hong Kong, Pok Fu Ram, Hong Kong

  • University of Tsukuba Hospital

    RECRUITING

    Tsukuba, ㅊ Ibaraki, 305-8576, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.